Koichi S Kobayashi

9PUBLICATIONS
19CO-AUTHORS
Liquid biopsiesInnate immunityMetabolic medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 15, 2025
Bacterial Therapeutics: Addressing the Affordability Gap in Cancer Therapy.

Kejsi Prifti, Chiswili Yves Chabu, Koichi S Kobayashi

|Mar 10, 2024
NLRC5/MHC class I transactivator: A key target for immune escape by SARS-CoV-2.

Baohui Zhu, Ryota Ouda, Yusuke Kasuga

|Feb 01, 2024
Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I.

Xin Sun, Toshiyuki Watanabe, Yoshitaka Oda

|Jun 06, 2023
FBXO11 constitutes a major negative regulator of MHC class II through ubiquitin-dependent proteasomal degradation of CIITA.

Yusuke Kasuga, Ryota Ouda, Masashi Watanabe

|Nov 16, 2021
SARS-CoV-2 inhibits induction of the MHC class I pathway by targeting the STAT1-IRF1-NLRC5 axis.

Ji-Seung Yoo, Michihito Sasaki, Steven X Cho

Pageof 2